Fast and High-Resolution Reversed-Phase Separation of Synthetic Oligonucleotides

Similar documents
Fast and Efficient Peptide Mapping of a Monoclonal Antibody (mab): UHPLC Performance with Superficially Porous Particles

Faster Separations Using Agilent Weak Cation Exchange Columns

Application Note. Authors. Abstract. Introduction. Pharmaceutical

Reversed-phase Separation of Intact Monoclonal Antibodies Using Agilent ZORBAX Rapid Resolution High Definition 300SB-C8 1.

Application of Agilent AdvanceBio Desalting-RP Cartridges for LC/MS Analysis of mabs A One- and Two-dimensional LC/MS Study

Peptide Mapping of Glycoprotein Erythropoietin by HILIC LC/MS and RP-LC/MS

Reproducible LC/MS Peptide Separation Using Agilent AdvanceBio Peptide Plus Columns

High Resolution LC or LC-MS Analysis of Oligonucleotides and Large DNA Fragments Using a New Polymer-Based Reversed Phase Column

Separation of Recombinant Human Erythropoietin (repo) Using Agilent Bio SEC-3

PLRP-S Polymeric Reversed-Phase Column for LC/MS Separation of mabs and ADC

Analysis of Intact and C-terminal Digested IgG1 on an Agilent Bio MAb 5 µm Column

AdvanceBio Peptide Mapping

Rapid UHPLC Analysis of Reduced Monoclonal Antibodies using an Agilent ZORBAX Rapid Resolution High Definition (RRHD) 300SB-C8 Column

Precise Characterization of Intact Monoclonal Antibodies by the Agilent 6545XT AdvanceBio LC/Q-TOF

Application Note. Biopharma. Authors. Abstract. James Martosella, Phu Duong Agilent Technologies, Inc Centreville Rd Wilmington, DE 19808

Fast, Low Pressure Analysis of Food and Beverage Additives Using a Superficially Porous Agilent Poroshell 120 EC-C18 Column

Fast Analysis of Environmental Phenols with Agilent Poroshell 120 EC-C18 Columns

Method Translation in Liquid Chromatography

BioHPLC columns. Tim Rice Biocolumn Technical Specialist

Separate and Quantify Rituximab Aggregates and Fragments with High-Resolution SEC

Sean M. McCarthy and Martin Gilar Waters Corporation, Milford, MA, U.S. INTRODUCTION EXPERIMENTAL RESULTS AND DISCUSSION

Clone Selection Using the Agilent 1290 Infinity Online 2D-LC/MS Solution

EPA 8330A Analysis of Explosives Using Agilent Poroshell 120 EC-CN and EC-C18 Columns

Biotherapeutic Method Development Guide

4/4/2013. BioHPLC columns. Paul Dinsmoor Biocolumn Technical Specialist. April 23-25, Size Exclusion BioHPLC Columns

Agilent AdvanceBio SEC Columns for Aggregate Analysis: Instrument Compatibility

Martin Gilar Waters Corporation, Milford, MA, U.S. Origins of synthetic oligonucleotides impurities. Lab-scale isolation options

Fast and High Resolution Analysis of Intact and Reduced Therapeutic Monoclonal Antibodies (mabs)

Biotherapeutic Method Development Guide

ADVANCE ACCURACY AND PRODUCTIVITY FOR FASTER ANALYSIS

Performance Characteristics of the Agilent 1220 Infinity Gradient LC system

Analysis of Monoclonal Antibody (mab) Using Agilent 1290 Infinity LC System Coupled to Agilent 6530 Accurate-Mass Quadrupole Time-of-Flight (Q-TOF)

High-throughput and Sensitive Size Exclusion Chromatography (SEC) of Biologics Using Agilent AdvanceBio SEC Columns

Characterize mab Charge Variants by Cation-Exchange Chromatography

Agilent PL-SAX Anion-Exchange Media for Nucleotide and Oligonucleotide Analysis

ADVANCE ACCURACY AND PRODUCTIVITY FOR FASTER ANALYSIS

Chromatography column for therapeutic protein analysis

DNAPac PA200 and PA200 RS Columns Solutions for Nucleic Acid Analysis

Analysis of Nucleosides Using an Agilent Infinity II High Speed UHPLC with the 6130 Single Quadrupole Mass Selective Detector

Size Exclusion BioHPLC columns Ion Exchange BioHPLC columns

Characterization of Glycosylation in the Fc Region of Therapeutic Recombinant Monoclonal Antibody

Emulation of the Agilent 1100 Series LC Through Waters Empower Software Analysis of an Analgesic Mixture

Disulfide Linkage Analysis of IgG1 using an Agilent 1260 Infinity Bio inert LC System with an Agilent ZORBAX RRHD Diphenyl sub 2 µm Column

Biomolecule Purification. Purification columns and media for peptides, oligonucleotides, and proteins

Agilent Prep LC Columns for Small Molecules and Biomolecules MAINTAIN RAPID, RELIABLE SEPARATIONS AS YOU SCALE-UP

Development of Analysis Methods for Therapeutic Monoclonal Antibodies Using Innovative Superficially Porous Particle Biocolumns

EPA Method 543: Selected Organic Contaminants by Online SPE LC/MS/MS Using the Agilent Flexible Cube

Characterize Fab and Fc Fragments by Cation-Exchange Chromatography

Preparative Purification of Corticosteroids by HPLC; Scalability and Loadability Using Agilent Prep C18 HPLC Columns Application

Profiling Glycosylation of Monoclonal Antibodies at Three Levels Using the Agilent 6545XT AdvanceBio LC/Q TOF

Choosing the Right Calibration for the Agilent Bio SEC-3 Column

Benefits of 2D-LC/MS/MS in Pharmaceutical Bioanalytics

Determination of Asarinin in Xixin (Asari Radix Et Rhizoma)

Cell Clone Selection Using the Agilent Bio-Monolith Protein A Column and LC/MS

Peptide Mapping: A Quality by Design (QbD) Approach

Separation of Native Monoclonal Antibodies and Identification of Charge Variants:

Size Exclusion Chromatography of Biosimilar and Innovator Insulin Using the Agilent AdvanceBio SEC column

A Comprehensive Workflow to Optimize and Execute Protein Aggregate Studies

Optimizing Protein Separations with Agilent Weak Cation-Exchange Columns

Application Note. Abstract. Authors. Introduction. Environmental

Inertsil ODS-3 2 µm. Base Silica Physical Properties and Chemical Modification. Base Silica: High Purity Silica Gel % Surface Area: 450 m 2 /g

Reducing Cycle Time for Charge Variant Analysis of Monoclonal Antibodies

Quantification of Host Cell Protein Impurities Using the Agilent 1290 Infinity II LC Coupled with the 6495B Triple Quadrupole LC/MS System

Charge Heterogeneity Analysis of Rituximab Innovator and Biosimilar mabs

EPA Method 540: Selected Organic Contaminants Using Agilent Plexa Cartridges and the Agilent 6460 Triple Quadrupole LC/MS

Multiple Detector Approaches to Protein Aggregation by SEC

Application Note. Author. Abstract. Biotherapeutics and Biologics. Sonja Schneider Agilent Technologies, Inc. Waldbronn, Germany

Analysis of amoxicillin and five impurities on the Agilent 1220 Infinity LC System

Peptide Mapping. Hardware and Column Optimization

Oligonucleotide Separation Technology

High-resolution Analysis of Charge Heterogeneity in Monoclonal Antibodies Using ph-gradient Cation Exchange Chromatography

Analysis of Monoclonal Antibody N-glycans by Fluorescence Detection and Robust Mass Selective Detection Using the Agilent LC/MSD XT

High-Throughput LC/MS Purification of Pharmaceutical Impurities

Cell Culture Optimization Using an Agilent Bio-Monolith Protein A Column and LC/MS

Agilent 1290 Infinity Quaternary LC Support of Columns with 2.1 to 4.6 mm ID to 1200 bar

ZORBAX StableBond HPLC Columns

mab Titer Analysis with the Agilent Bio-Monolith Protein A Column

Automated Scouting of Stationary and Mobile Phases Using the Agilent 1290 Infinity II Method Development Solution

Improving Retention Time Precision and Chromatography of Early Eluting Peptides with Acetonitrile/Water Blends as Solvent B

Developing Purification Strategies for the Agilent 1260 Infinity II Preparative LC/MSD System

Bio-Monolith Protein G Column - More Options for mab Titer Determination

Fast mass transfer Fast separations High throughput and improved productivity Long column lifetime Outstanding reproducibility Low carryover

Agilent 6430 Triple Quadrupole LC/MS System

Automated alternating column regeneration on the Agilent 1290 Infinity LC

Improved Peptide Maps Using Core-Shell Media: Explaining Better Biopharmaceutical Applications With Kinetex C18 Columns

Application Note. Authors. Abstract. Ravindra Gudihal Agilent Technologies India Pvt. Ltd. Bangalore, India

Technical Overview. Author. Abstract. Edgar Naegele Agilent Technologies, Inc. Waldbronn, Germany

A Highly Accurate Mass Profiling Approach to Protein Biomarker Discovery Using HPLC-Chip/ MS-Enabled ESI-TOF MS

Clearly better LC/MS solutions

Analysis and Purification of Polypeptides by Reversed-Phase HPLC

Purification of oligonucleotides by anion exchange chromatography

ph gradient analysis of IgG1 therapeutic monoclonal antibodies using a 5 µm WCX column

Quality-by-Design-Based Method Development Using an Agilent 1290 Infinity II LC

Critical Quality Attribute Assessment by Peptide Mapping Using LC/MS with Superficially Porous Columns

Higher Order mab Aggregate Analysis using New Innovative SEC Technology

Quantification of genotoxic "Impurity D" in Atenolol by LC/ESI/MS/MS with Agilent 1200 Series RRLC and 6410B Triple Quadrupole LC/MS

AdvanceBio HIC: a Hydrophobic HPLC Column for Monoclonal Antibody (mab) Variant Analysis

Method Transfer from an Agilent 1200 Series LC to an Agilent 1260 Infinity II LC

Purification of Oligonucleotides by Ion-pair Chromatography on Hybrid Silica Particles

Seamless Method Transfer from an Agilent 1260 Infinity Bio-inert LC to an Agilent 1260 Infinity II Bio-inert LC

Transcription:

Fast and High-Resolution Reversed-Phase Separation of Synthetic Oligonucleotides High-pH-stable, superficially porous particle columns for LC/UV and LC/MS Application Note Biologics and Biosimilars Authors Phu Duong, Brian A. Bidlingmeyer, Alex Zhu, and Stephen Luke Agilent Technologies, Inc. Introduction Synthetic DNA- and RNA-based oligonucleotides are among many successful biotherapeutic drugs to treat many different kinds of illnesses. They are synthesized in a multistep process. Although coupling efficiencies are high, the overall yield of oligos decreases as the number of cycles increases, with failure in coupling with single (N-1) and double (N-) deletions as the major impurities. To ensure drug potency, and to reduce the potential for drug interactions, a high-purity product is required, therefore, analyzing the purity of the products is important. There are many methods used for analyzing oligonucleotides. One of the most common involves anion-exchange chromatography. This can provide high resolution, but the separation often takes a long time. Moreover, due to its solvent systems, eluting oligonucleotides with high salt concentrations make this method incompatible with mass-spectrometry. This makes the identification of oligonucleotides and their impurities very cumbersome. In this application note, we demonstrate fast and high-resolution separation and identification of a number of de-protected (removal of the dimethoxytrityl group (DMT)) DNA and RNA oligonucleotides, using Agilent AdvanceBio Oligonucleotide columns. These are high-ph-stable reversed-phase columns packed with superficially porous Poroshell particles. The particles have a porous outer layer and solid core that limit diffusion distance, and, in combination with a very narrow particle size distribution, improve separation speed and chromatographic efficiency. With.7 µm diameter particles and 6 bar pressure rating, the columns are easily operated on HPLC and UHPLC instruments.

The Poroshell particles are chemically modified using proprietary technology that makes them very resistant to high-ph mobile phases up to ph 11.. The endcapped C18 bonded phase and 1Å pore diameter provide excellent selectivity for oligonucleotides. The data here include the separation and identification of DNA and RNA oligonucleotides using two popular mobile phase gradients. The eluents are volatile and MS compatible. One contains triethylammonium acetate (TEAA) commonly used in LC/UV separations, and the other contains hexafluoroisopropanol and triethylamine (HFIP:TEA), commonly used in LC/MS analysis for oligonucleotides. The LC/MS data also demonstrate excellent mass accuracy and provide sequence information of some oligonucleotides. Results are compared to the separation on a totally porous, hybrid particle column. Materials and Methods The column was an AdvanceBio Oligonucleotide,.1 mm (p/n 697-7). Acetonitrile, methanol, TEAA, HFIP, and TEA were purchased from Sigma-Aldrich, Corp. The DNA samples were DNA oligonucleotides (Agilent Oligonucleotide Ladder Standard, p/n 19-99) (Table 1). The 3-mer RNA used in the column comparison and the -mer DNA used for the MS data are from NASD, Boulder. The RNA samples were RNA oligonucleotides (Agilent Oligonucleotide Resolution Standard, p/n 19-98) (Table ). LC/UV conditions Mobile phase: A) 1 mm TEAA in water B) 1 mm TEAA in acetonitrile.6 ml/min (or other flow rates) Stop time: Post run: min Column temperature: 6 C Injection: Detection: UV at 6 nm LC/MS friendly conditions Mobile phase: A) HFIP:TEA ( mm:1 mm) in water B) methanol:mobile phase A (:). ml/min 3 to % B in. min, to 7% B in min -mer DNA Temperature: 6 C Detection: MS, or UV at 6 nm Min range: m/z Max range: 1,7 m/z Scan rate: 3. spectra/s Ion polarity: -ve VCap: 3, Nozzle voltage: 1, V Fragmentor: Instruments Agilent 19 Infinity LC Agilent 63 Accurate Mass Q-TOF LC/MS Table 1. DNA-oligonucleotide characteristics. Sequence Sequence Purity guarantee Amount (nmole) 1-mer TTTTT TTTTT TTTTT >8% -mer TTTTT TTTTT TTTTT TTTTT >8% -mer TTTTT TTTTT TTTTT TTTTT TTTTT >8% 3-mer TTTTT TTTTT TTTTT TTTTT TTTTT TTTTT >8% 3-mer TTTTT TTTTT TTTTT TTTTT TTTTT TTTTT TTTTT >8% -mer TTTTT TTTTT TTTTT TTTTT TTTTT TTTTT TTTTT TTTTT >8% Table. RNA-oligonucleotide characteristics. Sequence Sequence Purity guarantee Amount (nmole) 1-mer rcrarcrurgrararurarcrcrararu >8% 17-mer rurcrarcrarcrurgrararurarcrcrararu >8% -mer rurcrarurcrarcrarcrurgrararurarcrcrararu >8% 1-mer rgrurcrarurcrarcrarcrurgrararurarcrcrararu >8%

Results and Discussion Resolving N and N-1 oligonucleotides Separation of RNA oligonucleotides The oligonucleotide resolution standard contains four RNA oligonucleotides ranging from 1- to 1-mer, and is designed for verification of instrument and column performance (lot-to-lot) for analysis of synthetic oligonucleotides. Figure 1 illustrates the separation power of the AdvanceBio Oligonucleotide column for this standard. All peaks were separated in under nine minutes; the peaks were sharp and well resolved. The N and N-1 RNA oligonucleotides (1- and -mer) were separated close to baseline. These data suggest that the column was very capable of resolving a main oligonucleotide from its impurities. Separation of DNA oligonucleotides Another demonstration of the resolving capacity of complex samples by AdvanceBio Oligonucleotide is provided by the separation of an Oligonucleotide Ladder Standard that contains six DNA oligonucleotides, ranging from 1- to -mer. Figure demonstrates that the separation of all six oligonucleotides was completed in less than eight minutes. All the peaks were separated with baseline resolution. The 1-mer DNA oligonucleotide began to elute in as little as two minutes, and the - and -mer were eluted at four and five minutes, respectively. These data indicate that AdvanceBio Oligonucleotide columns are suitable for high throughput use in separating oligonucleotides. Absorbance (UV 6 nm) N (1-mer) 1 N (-mer) 1 1 3 6 7 8 9 1 to 1% B in 1 min Stop time: 11 min Agilent Oligonucleotide Resolution Standard 1-mer, 17-mer, -mer, 1-mer RNA (p/n 19-98) Injection: 1 µl min Figure 1. Separation of Agilent Oligonucleotide Resolution Standard using an Agilent AdvanceBio Oligonucleotide column. Absorbance (UV 6 nm) 1 1 1-mer -mer -mer 3-mer 3-mer -mer 1 3 6 7 8 6 to 8% B in 1 min Stop time: 13 min Agilent Oligonucleotide Ladder Standard 1-mer, -mer, -mer, 3-mer, 3-mer, -mer DNA (p/n 19-99) Injection:. µl Figure. Separation of Agilent Oligonucleotide Ladder using an Agilent AdvanceBio Oligonucleotide column. min 3

Mass-spectrometry compatibility To confirm the identity and purity of the newly produced and replica-production lots of oligonucleotides, mass spectrometry is used for the analysis. Figure 3 shows the MS results from a single DNA oligonucleotide of -mer. The AdvanceBio Oligonucleotide column generated high chromatographic resolution for the -mer DNA oligo peak and its impurities in only about three minutes. The UV and TIC traces, with the expansion view of the baselines, were recorded and reported. The expansion of baseline resolution of the main peak and N-peaks indicated that the two traces were very similar, and that they closely lined up. The compatibility between two types of detection showed that the UV trace had sufficient sensitivity to be used for ladder runs to determine the main peak and its impurities (N minuses peaks) without using the MS again, once the MS data was fully established. Figure shows the deconvoluted data from the TIC traces with fully labeled peaks and Table 3 shows the accurate masses and percentages of structures in the analysis from the main peak of the -mer DNA oligonucleotide and its impurities. The sum of this table demonstrated that the column provides 1% recovery. Absorbance (UV 6 nm) 8 A UV full scale 7 6 3 1 1 Response 3 1 3 1 C UV-expansive baseline 3.138 1 B TIC-expansion baseline Response 6 8 Time (min)...6.8 1. 1. 1. 1.6 1.8....6.8 Acquisition time (min) Figure 3. Separation of -mer DNA oligonucleotide using MS-compatible solvent. Counts 1.. 3. 3... 1. 1.. ******TTTGCTGCTGTTTTGCTGT FLP-19 FLP-18 FLP-17 FLP-16 FLP-1 FLP-1 FLP-13 FLP-1 FLP-11 FLP-1 FLP-9 FLP-8 FLP-7 FLP-6 FLP-3 to FLP-..6.8 1. 1. 1. 1.6 1.8....6 Acquisition time (min) Figure. Deconvoluted data from TIC of a -mer DNA oligonucleotide separated by the Agilent AdvanceBio Oligonucleotide column. Table 3. MS analysis and recovery. Peak Response % FLP 89897.33 FLP-1 166 1. FLP- 319.6 FLP-3 3388.6 FLP- 183 1.9 FLP- 1136.98 FLP-6 1.91 FLP-7 1137.96 FLP-8 1331 1.17 FLP-9 138 1.17 FLP-1 18697 1.63 FLP-11 38833 3.1 FLP-1 169.19 FLP-13 78.38 FLP-1 1636 3.63 FLP-1 38.7 FLP-16 3333.6 FLP-17 338 3.1 FLP-18 93. FLP-19 18 3.68 Sum 11876 1 FLP-1 FLP

Column comparison Superficially porous particles are known to have faster mass transfer due to the nature of the particles construction, that is, a solid core surrounded by a thin porous layer that allows shorter distances for diffusion into and out of the porous structure. Figure compares separations of 3-mer RNA oligonucleotide between the AdvanceBio Oligonucleotide with.7 µm particles and a totally hybrid porous.1 mm column with 1.7 µm totally porous hybrid particles. Data indicate that the peak width of the 3-mer RNA oligonucleotide on the AdvanceBio Oligonucleotide column was narrower than that generated by the 1.7 µm totally hybrid porous particle C18 column. This supports the fact that shorter distances for diffusion into and out of the superficially porous stationary phase result in faster mass transfer, producing peaks with higher resolution. The.7 µm particle size of the AdvanceBio Oligonucleotide column permitted operation at a lower backpressure compared to the 1.7 µm totally hybrid particle C18 column, 18 bar versus 9 bar at. ml/min, respectively. Therefore, AdvanceBio Oligonucleotide columns are compatible with 6 bar HPLC systems, as well as 1 bar HPLC systems for fast and high-speed separation. Absorbance (UV 6 nm) Absorbance (UV 6 nm) 17 1 1 1 7 1 8 6 Competitor oligonucleotide column, 1.7 totally hybrid porous particle C18 RT = 11.3 min PW =.18 min P = 9 bar Agilent AdvanceBio Oligonucleotide column RT = 13. min PW =.16 min P = 18 bar 6 8 1 1 1 Absorbance (UV 6 nm) Absorbance (UV 6 nm) 8 6 8 6 8 9 1 11 1 13 1 1 Injection: to % B in 1 min.6 ml/min 3-mer RNA 1 µl (from. mg/ml) Figure. Comparing the -mer DNA oligonucleotide separation on an AdvanceBio Oligonucleotide.7 µm column versus a 1.7 µm totally hybrid porous particle C18 column using HFIP:TEA in the mobile phases.

Column stability Figure 6 shows column stability and comparison data between the AdvanceBio Oligonucleotide column and the. µm totally hybrid porous particle C18 column, both with.1 mm dimensions. Data were collected from ~ consecutive injections of -mer DNA oligo at 6 C. The peak retention time was recorded and showed that the AdvanceBio Oligonucleotide column generated stable, nearly unchanged, and highly reproducible peak retention times, slightly better than that of the competitor oligonucleotide column,. µm totally hydrid porous particle C18. These stability data suggest that the AdvanceBio Oligonucleotide column has a long and comparable lifetime to the. µm totally hybrid porous column....3..1. 3.9 3.8 3.7 3.6 3....3..1. 3.9 3.8 3.7 3.6 3. Competitor oligonucleotide column,. µm totally hydrid porous particle C18 1 1 3 3 No. of injections AdvanceBio Oligonucleotide column,.7 µm 1 1 3 3 No. of injections Run time: Injection:.69 ml/min 7 to 11% B in min 8. min -mer RNA 1 µl of. mg/ml Figure 6. Column stability study. Conclusions The AdvanceBio Oligonucleotide column,.7 µm, with highly stable ph superficially-porous particles is designed for separating deprotected RNA and DNA oligonucleotides of different sizes with speed and high resolution. The columns can be used with both LC/UV and LC/MS mobile phases containing high ph iron-paring agents such as TEAA and HFIA:TEA (>ph 8.), the ideal ph for analyzing oligonucleotides. The AdvanceBio Oligonucleotide column was also shown to have the chemistry that delivers exceptional sample resolution and superior column lifetime. With.7 µm particles, the columns are compatible with 6 bar HPLC, and 1, bar UHPLC systems. AdvanceBio Oligonucleotide columns are packed in various column dimensions, which provide many selection options to meet various demands of isolation and analysis for both DNA- and RNA-based oligonucleotides. For More Information These data represent typical results. For more information on our products and services, visit our Web site at www.agilent.com/chem. www.agilent.com/chem For Research Use Only. Not for use in diagnostic procedures. Agilent shall not be liable for errors contained herein or for incidental or consequential damages in connection with the furnishing, performance, or use of this material. Information, descriptions, and specifications in this publication are subject to change without notice. Agilent Technologies, Inc., 1, 17 Printed in the USA November, 17 991-66EN